Novavax

NOVAVAX INC

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Bulls and Bears 1

News

Markets

$BTC

AMAT

ANET

AVGO

COIN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRVL

MSFT

NVAX

NVDA

ORCL

SMCI

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

SRPT

Benzinga examined the prospects for many investors&#39; favorite stocks over the last week — here&#39;s a look at some of our top stories.

Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets

Novavax,Vaccine,For,Prevention,Of,Coronavirus,,Covid-19,,Sars-cov-2,In,Doctors

Biotech

Earnings

Guidance

Health Care

Movers

Trading Ideas

General

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year outlook raised above expectations.

COVID Vaccine Maker Novavax Stock Soars 16% - Here&#39;s Why

Stock,Market,Or,Forex,Trading,Graph,And,Candlestick,Chart,Suitable

Equities

ASST

CVNA

GOOG

GOOGL

QBTS

D-Wave Quantum Inc. (NYSE:QBTS), Asset Entities, Inc. (NASDAQ:ASST), Alphabet, Inc.

Thursday&#39;s Top 5 Trending Stocks: What&#39;s Going On With D-Wave, Novavax, Carvana?

Novavax Inc

Press Releases

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025

Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Novavax to Participate in Upcoming March Investor Conferences

Novavax Announces Changes to Board of Directors

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

Novavax Appoints Charles Newton to Board of Directors

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

Novavax to Participate in BofA Securities 2025 Health Care Conference

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

Ardelyx

Bicara Therapeutics

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Geron

GRAIL

Gyre Therapeutics

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Janux Therapeutics

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

MannKind

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

JP Morgan

HC Wainwright & Co.

Jefferies

B. Riley Securities

B of A Securities

Comments

Novavax

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell